company background image
LTRN logo

Lantern Pharma NasdaqCM:LTRN Stock Report

Last Price

US$9.78

Market Cap

US$105.1m

7D

11.1%

1Y

111.7%

Updated

27 Mar, 2024

Data

Company Financials +

Lantern Pharma Inc.

NasdaqCM:LTRN Stock Report

Market Cap: US$105.1m

LTRN Stock Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.

LTRN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Lantern Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lantern Pharma
Historical stock prices
Current Share PriceUS$9.78
52 Week HighUS$11.99
52 Week LowUS$2.38
Beta1.27
1 Month Change127.44%
3 Month Change122.78%
1 Year Change111.69%
3 Year Change-46.09%
5 Year Changen/a
Change since IPO-34.58%

Recent News & Updates

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Recent updates

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Nov 06
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jul 20
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

Shareholder Returns

LTRNUS BiotechsUS Market
7D11.1%0.9%0.4%
1Y111.7%10.3%28.8%

Return vs Industry: LTRN exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: LTRN exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is LTRN's price volatile compared to industry and market?
LTRN volatility
LTRN Average Weekly Movement20.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: LTRN's share price has been volatile over the past 3 months.

Volatility Over Time: LTRN's weekly volatility has increased from 14% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201321Panna Sharmahttps://www.lanternpharma.com

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.

Lantern Pharma Inc. Fundamentals Summary

How do Lantern Pharma's earnings and revenue compare to its market cap?
LTRN fundamental statistics
Market capUS$105.05m
Earnings (TTM)-US$15.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LTRN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$15.96m
Earnings-US$15.96m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.49
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LTRN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.